Prevention of corneal neovascularization: Comparison of different doses of subconjunctival bevacizumab with its topical form in experimental rats

Ophthalmic Research

Volumn 46, Issue 1, 2011, Pages 50-54

  Hashemian, Mohammad Naser ^a   Z Mehrjardi, Hadi ^a,b   Moghimi, Sasan ^a   Tahvildari, Maryam ^a,b   Mojazi Amiri, Hoda ^a,b  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Avastin; Chemical cauterization; Corneal neovascularization; Subconjunctival injection; Topical bevacizumab

Indexed keywords

BEVACIZUMAB;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CAUTERIZATION; CHEMICAL BURN; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; CORNEA BURN; CORNEA INJURY; CORNEA NEOVASCULARIZATION; DRUG ADMINISTRATION ROUTE; DRUG DOSE COMPARISON; INFLAMMATION; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; TREATMENT OUTCOME;

ADMINISTRATION, TOPICAL; ANGIOGENESIS INHIBITORS; ANIMALS; ANTIBODIES, MONOCLONAL; CONJUNCTIVA; CORNEAL NEOVASCULARIZATION; DISEASE MODELS, ANIMAL; FEMALE; INJECTIONS, INTRAOCULAR; MALE; OPHTHALMIC SOLUTIONS; RATS; RATS, SPRAGUE-DAWLEY; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 78650880743     PISSN: 00303747     EISSN: 14230259     Source Type: Journal    
DOI: 10.1159/000322061     Document Type: Article

References (34)

1. Chang JH, Gabison EE, Kato T, Azar DT: Corneal neovascularization. Curr Opin Ophthalmol 2001;12:242-249. (Pubitemid 32751680)
2. Lee P, Wang CC, Adamis AP: Ocular neovascularization: an epidemiologic review. Surv Ophthalmol 1998;43:245-269. (Pubitemid 28558273)
3. Cursiefen C, Kuchle M, Naumann GO: Angiogenesis in corneal diseases: histopathologic evaluation of 254 human corneal buttons with neovascularization. Cornea 1998;17:611-613. (Pubitemid 28511907)
4. Liesegang TJ: Epidemiology of ocular herpes simplex: natural history in Rochester, Minn, 1950 through 1982. Arch Ophthalmol 1989;107:1160-1165.
5. Kvanta A, Sarman S, Fagerholm P, Seregard S, Steen B: Expression of matrix metalloproteinase-2 (MMP-2) and vascular endothelial growth factor (VEGF) in inflammation-associated corneal neovascularization. Exp Eye Res 2000;70:419-428. (Pubitemid 30658885)
6. Gan L, Fagerholm P, Palmblad J: Vascular endothelial growth factor (VEGF) and its receptor VEGFR-2 in the regulation of corneal neovascularization and wound healing. Acta Ophthalmol Scand 2004;82:557-563. (Pubitemid 39386968)
7. Edelman JL, Castro MR, Wen Y: Correlation of VEGF expression by leukocytes with the growth and regression of blood vessels in the rat cornea. Invest Ophthalmol Vis Sci 1999;40:1112-1123. (Pubitemid 29211448)
8. Wang Y, Fei D, Vanderlaan M, Song A: Biological activity of bevacizumab, a humanized anti-VEGF antibody in vitro. Angiogenesis 2004;7:335-345. (Pubitemid 40767935)
9. Ferrara N, Hillan KJ, Gerber HP, Novotny W: Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 2004;3:391-400. (Pubitemid 38618122)
10. Algvere PV, Steen B, Seregard S, Kvanta A: A prospective study on intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration of different durations. Acta Ophthalmol 2008;86:482-489.
11. Krebs I, Lie S, Stolba U, Zeiler F, Felke S, Binder S: Efficacy of intravitreal bevacizumab (Avastin) therapy for early and advanced neovascular age-related macular degeneration. Acta Ophthalmol 2009;87:611-617.
12. Modarres M, Nazari H, Falavarjani KG, Naseripour M, Hashemi M, Parvaresh MM: Intravitreal injection of bevacizumab before vitrectomy for proliferative diabetic retinopathy. Eur J Ophthalmol 2009; 19: 848-852.
13. Arevalo JF, Garcia-Amaris RA: Intravitreal bevacizumab for diabetic retinopathy. Curr Diabetes Rev 2009;5:39-46.
14. Beutel J, Peters S, Luke M, Aisenbrey S, Szurman P, Spitzer MS, Yoeruek E, Grisanti S: Bevacizumab as adjuvant for neovascular glaucoma. Acta Ophthalmol 2010;88:103-109.
15. Hosseini H, Nejabat M, Mehryar M, Yazdchi T, Sedaghat A, Noori F: Bevacizumab inhibits corneal neovascularization in an alkali burn induced model of corneal angiogenesis. Clin Experiment Ophthalmol 2007;35:745-748. (Pubitemid 350090533)
16. Doctor PP, Bhat PV, Foster CS: Subconjunctival bevacizumab for corneal neovascularization. Cornea 2008;27:992-995.
17. Hashemian MN, Moghimi S, Kiumehr S, Riazi M, Amoli FA: Prevention and treatment of corneal neovascularization: comparison of different doses of subconjunctival bevacizumab with corticosteroid in experimental rats. Ophthalmic Res 2009;42:90-95.
18. Bahar I, Kaiserman I, McAllum P, Rootman D, Slomovic A: Subconjunctival bevacizumab injection for corneal neovascularization. Cornea 2008;27:142-147. (Pubitemid 351158729)
19. Papathanassiou M, Theodossiadis PG, Liarakos VS, Rouvas A, Giamarellos-Bourboulis EJ, Vergados IA: Inhibition of corneal neovascularization by subconjunctival bevacizumab in an animal model. Am J Ophthalmol 2008;145:424-431.
20. You IC, Kang IS, Lee SH, Yoon KC: Therapeutic effect of subconjunctival injection of bevacizumab in the treatment of corneal neovascularization. Acta Ophthalmol 2009;87:653-658.
21. Kim TI, Kim SW, Kim S, Kim T, Kim EK: Inhibition of experimental corneal neovascularization by using subconjunctival injection of bevacizumab (Avastin). Cornea 2008;27:349-352. (Pubitemid 351440872)
22. Bock F, Konig Y, Kruse F, Baier M, Cursiefen C: Bevacizumab (Avastin) eye drops inhibit corneal neovascularization. Graefes Arch Clin Exp Ophthalmol 2008;246:281-284. (Pubitemid 351149633)
23. Ahmed A, Berati H, Nalan A, Aylin S: Effect of bevacizumab on corneal neovascularization in experimental rabbit model. Clin Experiment Ophthalmol 2009;37:730-736.
24. Kim SW, Ha BJ, Kim EK, Tchah H, Kim TI: The effect of topical bevacizumab on corneal neovascularization. Ophthalmology 2008;115:e33-e38.
25. Yoeruek E, Ziemssen F, Henke-Fahle S, Tatar O, Tura A, Grisanti S, Bartz-Schmidt KU, Szurman P: Safety, penetration and efficacy of topically applied bevacizumab: evaluation of eyedrops in corneal neovascularization after chemical burn. Acta Ophthalmol 2008;86:322-328. (Pubitemid 351785106)
26. Yoeruek E, Spitzer MS, Tatar O, Aisenbrey S, Bartz-Schmidt KU, Szurman P: Safety profile of bevacizumab on cultured human corneal cells. Cornea 2007;26:977-982. (Pubitemid 47329805)
27. Mahoney JM, Waterbury LD: Drug effects on the neovascularization response to silver nitrate cauterization of the rat cornea. Curr Eye Res 1985;4:531-535. (Pubitemid 15066517)
28. Manzano RP, Peyman GA, Khan P, Carvounis PE, Kivilcim M, Ren M, Lake JC, Chevez-Barrios P: Inhibition of experimental corneal neovascularisation by bevacizumab (Avastin). Br J Ophthalmol 2007;91:804-807. (Pubitemid 46846656)
29. Han YS, Lee JE, Jung JW, Lee JS: Inhibitory effects of bevacizumab on angiogenesis and corneal neovascularization. Graefes Arch Clin Exp Ophthalmol 2009;247:541-548.
30. Habot-Wilner Z, Barequet IS, Ivanir Y, Moisseiev J, Rosner M: The inhibitory effect of different concentrations of topical bevacizumab on corneal neovascularization. Acta Ophthalmol 2009, E-pub ahead of print.
31. Gadkari SS: Evaluation of 19 cases of inadvertent globe perforation due to periocular injections. Indian J Ophthalmol 2007;55:103-107.
32. Kayikcioglu O, Kayikcioglu M, Erakgun T, Guler C: Electrocardiographic changes during subconjunctival injections. Int Ophthalmol 1999;23:37-41.
33. Peters S, Heiduschka P, Julien S, Ziemssen F, Fietz H, Bartz-Schmidt KU, Schraermeyer U: Ultrastructural findings in the primate eye after intravitreal injection of bevacizumab. Am J Ophthalmol 2007;143:995-1002.
34. Koenig Y, Bock F, Horn F, Kruse F, Straub K, Cursiefen C: Short- and long-term safety profile and efficacy of topical bevacizumab (Avastin) eye drops against corneal neovascularization. Graefes Arch Clin Exp Ophthalmol 2009;247:1375-1382.